logo
What To Know About How Facial Fillers Impact Cosmetic Surgery

What To Know About How Facial Fillers Impact Cosmetic Surgery

Forbes2 days ago
If you're considering a facelift, whether now or in the future, you may want to keep reading this.
Non-invasive medical procedures, such as neuromodulators like Botox, hyaluronic acid fillers like Juvederm and biostimulators like Sculptra, have proliferated over the last decade and culturally supplanted face lifts as the primary method to achieve a youthful appearance. Recently, however, face lifts have made a comeback thanks to growing awareness of procedures like blepharoplasty, wherein a surgeon cuts into the creases of the eyelids, or deep-plane face lifts, which involve lifting and repositioning underlying tissues, including muscle and fat, and not just skin. In fact, there's a growing cohort of younger patients receiving facelifts. A recent report from the American Academy of Facial Plastic and Reconstructive Surgery found that roughly one-third of facelift patients are between 35 and 55.
Simultaneously, there is a growing body of evidence that fillers believed to be temporary do last longer in the body than previously understood. That has led to a larger conversation about how the treatments you receive today could impact a facelift procedure even a decade or more from now.
'It's very rare that I have a patient who's not done more than Botox or a chemical peel. I am more surprised when I treat a patient who's not had anything done,' said Dr. Lesley Rabach, board-certified facial plastic surgeon and co-owner of LM Medical.
While sources all agree that hyaluronic acid fillers are virtually a non-issue for facelifts because of where they are injected, some expressed concerns over products like Sculptra and Radiesse, PDO thread lift, and heat-based skin tightening treatments. The reason for this is that all of these treatments lead to a form of scar tissue because they trigger the body's inflammatory response to generate more collagen and heal the skin from its intentional micro-wounds.
There are 28 various types of collagen, but by far, the most common are types I through IV, with type I making up the majority found in the skin, providing its elasticity and firmness. Research shows that scar tissue is comprised mainly of collagen types I and III, but the fiber composition of the protein is different, hence the difference in texture and appearance from typical skin. If someone knows they want a facelift in the future, it's best to avoid procedures that create scarring, said Dr. Jimmy Sung, board-certified plastic surgeon and owner of Tribeca Aesthetics.
Sculptra and Radiesse in particular have benefited from marketing themselves as 'biostimulators,' referring to their ability to trigger the body to produce more collagen and replace lost volume. Sculptra is made of poly-L-lactic acid and directly provokes the body's inflammatory response. Meanwhile, Radiesse is made of calcium hydroxylapatite spheres suspended in a gel formula, which, when injected, also triggers a similar inflammatory response.
Introduced in the U.S. in 2004 and 2006, respectively, both products have benefited from the market decline in HA fillers and patients experiencing facial sallowness following GLP-1 use (and often referred to as 'Ozempic face'). Sculptra's first indication was for the restoration and correction of the signs of facial fat loss in people with human immunodeficiency virus (HIV). In 2009, Sculptra rebranded to Sculptra Aesthetic and received an approved FDA cosmetic indication for the correction of facial wrinkles due to aging.
'It's not good marketing to say this causes inflammation or scarring, so instead they say 'biostimulating.'... If there's a possibility [you'll get a facelift], then it's best to avoid it,' said Dr. Sung. 'But if you know you'll never have one, then yes, perhaps [you can receive it]. But I definitely don't think these products are suitable for young patients.'
One factor that's led to an issue for surgeons is the manner and location of biostimulators on the face. According to Dr. Bianca Molina, board-certified plastic surgeon and owner of Bianca Molina Plastic Surgery, Sculptra has been injected differently over the years in both depth and location, which influences its results. Because of this and the younger age of many facelift patients, the scar-like tissue is more visible to surgeons.
'The timeline on surgery has been moved way up to a younger age, so the effects of these injectables, [which are like] a scar reaction, or the actual product itself, is more present,' she said.
While she said she would not hold back on Sculptra for patients who are candidates now, provided they would not consider a facelift for at least a decade. However, she added that she would limit their treatments. Damage is always a risk for a facelift, regardless of cosmetic and health history, but when there are foreign substances in the face, it can heighten that risk. There can also be compromised aesthetic results, depending on the skill of the surgeon in dealing with such substances in the face, or if too much was injected. But that is a more severe outcome, she said.
But the one treatment she would never advise for patients who might have a facelift in the future is a PDO thread lift, which is polydioxanone dissolvable sutures that tighten sagging skin, particularly on the jaw and neck. She said she's generally 'not a fan' of the procedure regardless of a patient's interest in future facial surgery.
'I would never recommend it for anyone, ever, because it makes it very, very hard to do a good surgical procedure. I don't think those are ever worth it,' she said.
Dr. Rabach also agreed that a PDO thread lift is a more difficult situation to handle in surgery, and that non-invasive technologies that heat the skin, like Thermage, can also cause scar-like tissue, which poses a surgical challenge. In her opinion, Sculptra doesn't cause 'tremendous' scar tissue, but she does see it when she's performing a surgery. She advised waiting over a year for a surgical procedure if someone has received biostimulatory or skin-tightening treatments.
'I don't know so much if it impacts the results, unless it's somebody who's really been doing an excessive amount of all of it,' she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Novo Nordisk Stock Bumped Higher on Friday
Why Novo Nordisk Stock Bumped Higher on Friday

Yahoo

time25 minutes ago

  • Yahoo

Why Novo Nordisk Stock Bumped Higher on Friday

Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Bumped Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Addus HomeCare (ADUS) Q2 Earnings: What To Expect

Yahoo

time26 minutes ago

  • Yahoo

Addus HomeCare (ADUS) Q2 Earnings: What To Expect

Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

More than 9,000 Arlington ISD students receive free backpacks at back-to-school kickoff
More than 9,000 Arlington ISD students receive free backpacks at back-to-school kickoff

CBS News

time40 minutes ago

  • CBS News

More than 9,000 Arlington ISD students receive free backpacks at back-to-school kickoff

North Texas students can hit the snooze button for a few more mornings, but thousands of Arlington ISD families were up bright and early Saturday to prepare for the first day of school. Long lines of parents and students entered AT&T Stadium for the 11th annual Arlington ISD Back to School Kickoff. More than 9,000 students received backpacks filled with school supplies to help them start the school year on the right foot. In addition to backpacks, students received free haircuts, medical screenings and other services. The event aimed to ease the financial burden many families face at the start of the school year. "Being able to come and receive these backpacks filled with school supplies and get the health screenings is such a great blessing because a lot of things cost so much," said parent Patreece Dade. Xander Dade, a rising junior, said the backpack was packed with essentials. "It's heavy with certain surprises like binders, colored pencils, pencils, notebooks—things that I do need," he said. "Going into the new school year as a rising junior, we have the PSAT and important things that are coming up." The Gene and Jerry Jones Family Arlington Youth Foundation sponsored the event, which has provided more than 100,000 backpacks to students over the past 11 years. "Today was about ensuring that all of those resources are lined up so that we can take that load off of the student when they walk into our school buildings," said Arlington ISD Superintendent Dr. Matt Smith. "We want them to be able to focus on learning." Parents who missed the event and still need supplies can contact Arlington ISD's Family and Community Engagement department for assistance.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store